Situation Snapshot A new COVID-19 variant (Omicron) was recently identified in South Africa. On 11/26/21 the World Health Organization classified Omicron as a variant of concern (VOC). The decision … [Read more...] about Time For T cells: Gritstone Bio (GRTS)
grts
GRTS Transcript-Cowen 2021
Marc Farhm All right, we will. before we really get started, we'll wait for a second here to let everybody join the session. But welcome back to the fifth annual Callen IO Summit. Hopefully the … [Read more...] about GRTS Transcript-Cowen 2021
GRTS Transcript: Stifel 2021
Ben Burnett Hello everyone. My name is Ben Burnett, biotech analyst at Stifle and I'm pleased to be joined by Andrew Allen, CEO of Gritstone Gio. He's going to give a formal presentation and if … [Read more...] about GRTS Transcript: Stifel 2021
Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses
On 11/11/21 one of our core positions Gritstone Bio (GRTS) reported highly anticipated data from its CORAL COVID-19 vaccine program in non-human primates (NHPs). After scrupulous review and comparison … [Read more...] about Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses
Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
As mentioned in our last report, Gritstone Bio (GRTS) initially applied its next-generation heterologous (virus/sa-mRNA) vaccine technology to fight cancer. The thesis articulated by the founding … [Read more...] about Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
Gritstone Oncology (Nasdaq: GRTS) Investment Update
Here we reflect on the past quarter for GRTS. Subsequent to the Phase 1a/1b data update on 7/14/20 GRTS lost 50% of its market capitalization ($155M) in a single day with ~30% of outstanding … [Read more...] about Gritstone Oncology (Nasdaq: GRTS) Investment Update
You must be logged in to post a comment.